High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation

Journal of Infectious Diseases

Volumn 209, Issue 4, 2014, Pages 557-561

  Shmueli, Einat ^a   Or, Reuven ^a   Shapira, Michael Y ^a   Resnick, Igor B ^a   Caplan, Orit ^a   Bdolah Abram, Tali ^b   Wolf, Dana G ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

antiviral drug resistance; cytomegalovirus; hematopoietic stem cell transplantation

Indexed keywords

ANTIVIRAL DRUG RESISTANCE; CYTOMEGALOVIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROSPECTIVE STUDIES;

EID: 84893275395     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit475     Document Type: Conference Paper

References (15)

1. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113:5711-9.
2. Boeckh M. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology Am Soc Hematol Educ Program 2011; 2011:305-9.
3. Pollack M, Heugel J, Xie H, et al. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2011; 17:664-73.
4. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23:689-712.
5. Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997; 176:69-77.
6. Gilbert C, Roy J, Belanger R, et al. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrob Agents Chemother 2001; 45:3669-71.
7. van der Beek MT, Marijt EW, Vossen AC, et al. Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients. Antivir Ther 2012; 17:45-51.
8. Allice T, Busca A, Locatelli F, Falda M, Pittaluga F, Ghisetti V. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drugresistant cytomegalovirus. J Antimicrob Chemother 2009; 63:600-8.
9. Hantz S, Garnier-Geoffroy F, Mazeron MC, et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother 2010; 65:2628-40.
10. Koh LP, Chao N. Haploidentical hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42(Suppl 1):S60-3.
11. Shapira MY, Resnick IB, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008; 46: 1455-7.
12. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-7.
13. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103:2003-8.
14. Baron F, Storer B, Maris MB, et al. Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12: 1176-87.
15. Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005; 7:166-70.